Hims subscribers in 2026
Short Answer
Both the model and the market expect Hims subscribers to be above 2.8 million in 2026, with no compelling evidence of mispricing.
1. Executive Verdict
- Since last update (~24h): Model-led probability for above 3.08 million dropped 16.0pp, flipping its edge.
- Headline model probability decreased 2.0pp, flipping its edge and lowering confidence by 2.0pp.
- Model-led probabilities for all outcomes above 2.88 million decreased, flipping multiple edges.
- Hims subscribers likely exceed 2.8 million on anticipated H2 2026 GLP-1 growth.
- Elevated GLP-1 churn and FDA review temper highest subscriber growth projections.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 2.84 million | 95.0% | 94.0% | Market higher by 1.0pp |
| Above 3.08 million | 43.0% | 40.2% | Market higher by 2.8pp |
| Above 2.92 million | 90.0% | 88.1% | Market higher by 1.9pp |
| Above 2.8 million | 96.0% | 95.2% | Market higher by 0.8pp |
| Above 3.04 million | 55.0% | 51.3% | Market higher by 3.7pp |
Current Context
Hims & Hers reported subscriber growth and revenue in Q1 2026. As of Q1 2026, the company recorded nearly 2.6 million subscribers, an increase of 9% year-over-year [^][^][^]. Revenue for the first quarter of 2026 reached $608.1 million, up 4% year-over-year [^][^]. However, Hims & Hers posted a net loss of $92.1 million, driven by a strategic pivot toward branded GLP-1 medications [^][^].
The company projects substantial revenue and EBITDA for full-year 2026. Hims & Hers expects full-year 2026 revenue between $2.8 billion and $3.0 billion [^][^]. Adjusted EBITDA for the same period is forecast to range from $275 million to $350 million [^][^]. The company is scheduled to announce its Q2 2026 financial results on August 10, 2026 [^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This prediction market has been stable, trading in a narrow one-point range between 96% and 97% probability. The contract opened at 97% and has since settled at 96%, indicating a consistently high perceived likelihood of the event's occurrence. There have been no significant price spikes or drops. The price action suggests that recent fundamental data, such as the reported Q1 2026 subscriber count of nearly 2.6 million, was already priced in by market participants and did not introduce new volatility.
Trading volume is exceptionally light, with only 181 contracts traded across six data points. This low liquidity suggests limited market participation and a lack of opposing views strong enough to move the price out of its tight range. The price of 96% is acting as a firm support level, with 97% as immediate resistance.
The persistent high probability suggests a strong market consensus that Hims & Hers will meet the subscriber threshold specified by the contract for the 2026 resolution period. The lack of significant trading volume or price movement implies that the current pricing reflects a settled view among the few active participants, with little new information or capital entering to challenge it.
3. Market Data
Contract Snapshot
This market resolves YES if Hims & Hers Health Inc. reports over 3.04 million subscribers in 2026, and NO if they report 3.04 million or fewer. The outcome is verified from Fiscal.ai. The market closes early if the event occurs, otherwise by March 31, 2028, at 1:00 AM EDT, with payouts projected 30 minutes after closing; insider trading is prohibited.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 2.8 million | $0.99 | $0.06 | 96% |
| Above 2.84 million | $0.99 | $0.06 | 95% |
| Above 2.92 million | $0.94 | $0.13 | 90% |
| Above 2.88 million | $0.95 | $0.10 | 86% |
| Above 2.96 million | $0.89 | $0.17 | 83% |
| Above 3 million | $0.75 | $0.31 | 68% |
| Above 3.04 million | $0.63 | $0.42 | 55% |
| Above 3.08 million | $0.51 | $0.55 | 43% |
| Above 3.12 million | $0.99 | $1.00 | 0% |
| Above 3.16 million | $0.99 | $1.00 | 0% |
| Above 3.2 million | $0.99 | $1.00 | 0% |
Market Discussion
Hims & Hers reported nearly 2.6 million subscribers as of March 31, 2026, an increase of 9% year-over-year [^][^][^]. The company projects full-year 2026 revenue between $2.8 billion and $3.0 billion [^]. However, market sentiment as of July 2026 is mixed to bearish due to regulatory uncertainty surrounding peptides and compounded GLP-1 drugs, with an upcoming FDA advisory meeting on July 23-24, 2026, being a key focus [^][^].
4. How might the 2026 rollout of Hims' branded GLP-1 medications impact its subscriber growth rate and product mix?
| New weight loss subscribers (monthly) | Over 100,000 [^][^] |
|---|---|
| Total subscribers (Q1 2026) | 2.584 million at March 31, 2026 [^][^][^][^][^][^][^][^][^] |
| 2026 Revenue Guidance | $2.8–$3.0 billion [^][^][^][^][^][^][^][^][^] |
The 2026 introduction of branded GLP-1 medications is poised to significantly increase subscriber growth and shift the product mix towards weight-loss and branded offerings [^] [^] [^] [^] [^] [^] [^] [^] . While Hims has not provided specific subscriber projections directly tied to this rollout, the weight loss category reportedly attracted over 100,000 new subscribers monthly following its early 2026 launch [^][^]. By the end of Q1 2026, Hims & Hers had reached 2.584 million total subscribers, representing a 9% year-over-year increase [^][^][^][^][^][^][^][^][^].
Management anticipates accelerating growth from branded GLP-1 offerings. Growth is already progressing quickly with the expanded availability of branded GLP-1s, and further increases are expected, especially as weight loss shipments transition from a two-month to a one-month cadence in the latter half of 2026 [^][^][^][^][^][^][^]. This strategic move has diversified the product mix towards a broader, branded offering, enhancing user engagement, evidenced by nearly 90% of new branded GLP-1 users downloading the company's application [^][^]. New business is largely branded, with many previous compounded GLP-1 subscribers moving to branded alternatives, indicating a higher proportion of subscribers for weight-loss treatment and decreased reliance on compounded options [^][^][^][^][^][^][^].
Short-term costs are offset by confidence in long-term profitability and scalability. These costs include $33 million in restructuring expenses and a Q1 2026 GAAP net loss of $92 million [^]. Despite these immediate financial impacts, the company has shown strong confidence in branded GLP-1 adoption by raising its full-year 2026 revenue guidance to $2.8–$3.0 billion [^][^][^][^][^][^][^][^][^].
5. How do Hims & Hers' customer acquisition costs (CAC) in 2026 compare with those of its key telehealth competitor, Ro?
| Hims & Hers Estimated CAC | $290–$340 per subscriber (as of May 2026 [^]) |
|---|---|
| Ro Estimated CAC | $180–$220 (as of May 2026 [^]) |
| Hims & Hers LTV:CAC Ratio | 1.4–1.5x (as of May 2026 [^]) |
Hims & Hers' customer acquisition costs significantly exceed Ro's as of May 2026. Hims & Hers’ estimated blended customer acquisition cost (CAC) is $290–$340 per subscriber, a figure notably higher than its key competitor Ro’s estimated CAC of $180–$220. This difference is primarily attributed to Hims & Hers' substantial investment in paid media channels, including Meta, CTV, and influencer marketing. In contrast, Ro achieves a lower CAC by focusing more on organic channels, SEO, and referral traffic [^].
Ro currently demonstrates superior unit economics despite fewer subscribers than Hims & Hers. As of May 2026, Ro’s business model exhibits a more favorable unit economics profile, evidenced by a 2.0–2.2x LTV:CAC ratio, which surpasses Hims & Hers’ ratio of 1.4–1.5x. Despite having less favorable unit economics, Hims & Hers reported nearly 2.6 million subscribers by the first quarter of 2026. In comparison, private estimates place Ro’s subscriber count at approximately 1.4 million [^].
6. What has been the historical quarterly subscriber growth for Hims from Q1 2024 through Q1 2026, and what does this trend suggest for the rest of 2026?
| Subscribers Q1 2025 | 2.4 million [^][^][^] |
|---|---|
| Subscribers Q1 2026 | nearly 2.6 million [^][^][^] |
| Full-year 2026 Revenue Forecast | $2.8 billion-$3.0 billion [^][^][^][^] |
Hims & Hers experienced significant subscriber growth from Q1 2024 to Q1 2026. The company’s subscriber base grew from 1.7 million in Q1 2024 to 2.4 million in Q1 2025, and then reached nearly 2.6 million by Q1 2026 [^][^][^]. Despite this increase, the 9% year-over-year subscriber growth reported in Q1 2026 indicates a deceleration compared to its earlier, more rapid growth phases [^].
Management attributes subscriber growth deceleration to a strategic shift. This slowdown is primarily linked to the company's strategic pivot towards expanding its branded GLP-1 product offerings [^]. Looking ahead, executives project that growth will accelerate for the remainder of 2026, leading to an upward revision of their full-year 2026 revenue forecast to a range of $2.8 billion to $3.0 billion [^][^][^][^].
7. What official guidance has Hims & Hers management provided for full-year 2026 subscriber growth in its Q1 or upcoming Q2 earnings calls?
| Full-Year 2026 Revenue Guidance | $2.8 billion to $3.0 billion [^][^][^] |
|---|---|
| Q1 2026 Total Subscribers | Nearly 2.6 million [^][^] |
| Monthly Weight Loss Subscriber Addition | Over 100,000 [^][^][^][^] |
Hims & Hers management has not issued explicit 2026 subscriber count guidance. The company confirmed in its Q1 2026 earnings release and call transcript that it has not provided specific quantitative guidance for total subscriber counts for the full year 2026 [^][^][^][^]. Furthermore, there is no indication that an upcoming Q2 2026 earnings call will issue a formal subscriber key performance indicator (KPI) target for that year [^][^]. However, management reiterated a broader, long-term ambition to scale to "tens of millions of subscribers" over time [^][^].
While no overall target exists, weight loss subscriber growth is strong. During the Q1 2026 earnings call, management indicated they are on track to add over 100,000 new subscribers per month within their weight loss specialty [^][^][^][^]. In Q1 2026, the company reported a 9.00% year-over-year increase in total subscribers, reaching nearly 2.6 million [^][^].
8. What specific risks, such as regulatory scrutiny or competitive pressures mentioned in Hims' 2026 SEC filings, could threaten its subscriber growth targets?
| Regulatory Scrutiny | FDA oversight of compounded peptides [^][^], and general governmental regulation identified in Hims Hers Health, Inc. 10-Q May 2026 and 10-K February 2026 reports [^][^][^] |
|---|---|
| Competitive Pressure | High customer acquisition costs and the need to capture a significant percentage of new cash-pay patients [^][^] |
| GLP-1 User Churn | Elevated among oral GLP-1 users due to a subscription pricing step-up from $39 to $149 per month [^][^] |
Hims' 2026 subscriber growth targets face significant regulatory risks, particularly regarding its compounding pharmacy supply chain for GLP-1 medications [^] [^] . Specific concerns include FDA oversight of compounded peptides, a risk amplified by a strategic pivot and potential obsolescence of earlier inventory [^][^]. Hims' SEC filings, including its May 2026 10-Q Quarterly Report and February 2026 10-K Annual Report, additionally highlight general risks stemming from increased governmental regulation and legislative initiatives [^][^][^]. These broader regulatory pressures could negatively impact the company's ability to retain existing subscribers and acquire new ones [^][^][^].
Beyond regulatory concerns, Hims faces pressures on its subscriber growth model from competitive factors and high customer acquisition costs [^] [^] . – D2C Times" data-source-lanes="traditional">[^]. To achieve its 2026 subscriber targets, analysts suggest Hims must attract a considerable share of new cash-pay patients [^][^]. A primary risk to subscriber growth in 2026 also stems from elevated churn among oral GLP-1 (Wegovy) users [^][^]. This churn is largely attributed to a substantial increase in subscription pricing, rising from $39 in the initial month to $149 in subsequent months [^][^].
9. What Could Change the Odds
Key Catalysts
Hims & Hers reported nearly 2.6 million subscribers as of Q1 2026 (ended March 31, 2026), reflecting 9% year-over-year growth [^] [^] [^] . Reports First Quarter 2026..." data-source-lanes="traditional">[^][^][^]. For full-year 2026, revenue guidance was raised to a range of $2.8 billion to $3.0 billion, with adjusted EBITDA guidance set at $275 million to $350 million [^][^]. Key catalysts for 2026 include the integration of the Eucalyptus acquisition, the strategic distribution deal with Novo Nordisk for branded GLP-1 products, and regulatory outcomes regarding peptide compounding [^][^].
Bullish sentiment is driven by the company's platform scaling, successful branded GLP-1 transition, and international expansion via Eucalyptus [^] . Here’s What to Expect | TIKR.com" data-source-lanes="traditional">[^]. Bearish risks include potential regulatory restrictions on compounded peptides, stalling subscriber growth in the weight-loss segment, and failure to realize promised back-half EBITDA leverage [^][^][^].
Key Dates & Catalysts
- Expiration: March 31, 2028
- Closes: March 31, 2028
10. Decision-Flipping Events
- Trigger: Hims & Hers reported nearly 2.6 million subscribers as of Q1 2026 (ended March 31, 2026), reflecting 9% year-over-year growth [^] [^] [^] .
- Trigger: For full-year 2026, revenue guidance was raised to a range of $2.8 billion to $3.0 billion, with adjusted EBITDA guidance set at $275 million to $350 million [^] [^] .
- Trigger: Key catalysts for 2026 include the integration of the Eucalyptus acquisition, the strategic distribution deal with Novo Nordisk for branded GLP-1 products, and regulatory outcomes regarding peptide compounding [^] [^] .
- Trigger: The Eucalyptus acquisition closed in early June 2026 [^] .
12. Historical Resolutions
No historical resolution data available for this series.
